Nuclear Receptors in the Regulation of Lipid Metabolism

Current Cardiovascular Risk Reports

Volumn 4, Issue 2, 2010, Pages 142-149

  Mello, Tommaso ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

CAR; FXR; Lipids; LXR; Metabolism; Nuclear receptor; PPAR; PXR

Indexed keywords

EID: 84871339415     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-010-0080-1     Document Type: Review

References (55)

1. Germain P, Staels B, Dacquet C, et al.: Overview of nomenclature of nuclear receptors. Pharmacol Rev 2006, 58: 685-704.
2. Gronemeyer H, Gustafsson JA, Laudet V: Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004, 3: 950-964.
3. Ricote M, Glass CK: PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 2007, 1771: 926-935.
4. Sato O, Kuriki C, Fukui Y, Motojima K: Dual promoter structure of mouse and human fatty acid translocase/CD36 genes and unique transcriptional activation by peroxisome proliferator-activated receptor alpha and gamma ligands. J Biol Chem 2002, 277: 15703-15711.
5. Martin G, Schoonjans K, Lefebvre AM, et al.: Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem 1997, 272: 28210-28217.
6. Dreyer C, Krey G, Keller H, et al.: Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992, 68: 879-887.
7. Muerhoff AS, Griffin KJ, Johnson EF: The peroxisome proliferator-activated receptor mediates the induction of CYP4A6, a cytochrome P450 fatty acid omega-hydroxylase, by clofibric acid. J Biol Chem 1992, 267: 19051-19053.
8. Srivastava RA, Jahagirdar R, Azhar S, et al.: Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol Cell Biochem 2006, 285: 35-50.
9. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al.: PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996, 15: 5336-5348.
10. Fruchart JC: Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 2009, 205: 1-8.
11. Tontonoz P, Spiegelman BM: Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008, 77: 289-312.
12. Boden G, Homko C, Mozzoli M, et al.: Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes 2005, 54: 880-885.
13. Combs TP, Wagner JA, Berger J, et al.: Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 2002, 143: 998-1007.
14. Barroso I, Gurnell M, Crowley VE, et al.: Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999, 402: 880-883.
15. Agostini M, Schoenmakers E, Mitchell C, et al.: Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance. Cell Metab 2006, 4: 303-311.
16. Ehrenborg E, Krook A: Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor delta. Pharmacol Rev 2009, 61: 373-393.
17. Muoio DM, MacLean PS, Lang DB, et al.: Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta. J Biol Chem 2002, 277: 26089-26097.
18. Kramer DK, Al-Khalili L, Guigas B, et al.: Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J Biol Chem 2007, 282: 19313-19320.
19. Holst D, Luquet S, Nogueira V, et al.: Nutritional regulation and role of peroxisome proliferator-activated receptor delta in fatty acid catabolism in skeletal muscle. Biochim Biophys Acta 2003, 1633: 43-50.
20. Kleiner S, Nguyen-Tran V, Bare O, et al.: PPAR{delta} agonism activates fatty acid oxidation via PGC-1{alpha} but does not increase mitochondrial gene expression and function. J Biol Chem 2009, 284: 18624-18633.
21. Terada S, Wicke S, Holloszy JO, Han DH: PPARdelta activator GW-501516 has no acute effect on glucose transport in skeletal muscle. Am J Physiol Endocrinol Metab 2006, 290: E607-E611.
22. Kramer DK, Al-Khalili L, Perrini S, et al.: Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor delta. Diabetes 2005, 54: 1157-1163.
23. Leibowitz MD, Fievet C, Hennuyer N, et al.: Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett 2000, 473: 333-336.
24. Wallace JM, Schwarz M, Coward P, et al.: Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys. J Lipid Res 2005, 46: 1009-1016.
25. Tanaka T, Yamamoto J, Iwasaki S, et al.: Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A 2003, 100: 15924-15929.
26. •• Riserus U, Sprecher D, Johnson T, et al.: Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008, 57: 332-339. This 2-week randomized study demonstrates a greater efficacy for PPARβ/δ agonist versus PPARα agonists in the amelioration of several metabolic abnormalities in obese men.
27. Billin AN: PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home. Expert Opin Investig Drugs 2008, 17: 1465-1471.
28. Zhou J, Zhai Y, Mu Y, et al.: A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J Biol Chem 2006, 281: 15013-15020.
29. • Zhou J, Febbraio M, Wada T et al.: Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 2008, 134: 556-567. In this elegant work, CD36 is identified as a direct target of LXR and a converging point in the regulation of liver lipid metabolism by LXR, PXR, and PPARγ.
30. Inoue J, Satoh S, Kita M, et al.: PPARalpha gene expression is up-regulated by LXR and PXR activators in the small intestine. Biochem Biophys Res Commun 2008, 371: 675-678.
31. Nakamura K, Moore R, Negishi M, Sueyoshi T: Nuclear pregnane X receptor cross-talk with FoxA2 to mediate drug-induced regulation of lipid metabolism in fasting mouse liver. J Biol Chem 2007, 282: 9768-9776.
32. •• Moreau A, Teruel C, Beylot M, et al.: A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte. Hepatology 2009, 49: 2068-2079. This article demonstrates that activation of PXR promotes aberrant hepatic de novo lipogenesis via activation of the nonclassical S14 pathway.
33. Sookoian S, Castano GO, Burgueno AL, et al.: The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. Pharmacogenet Genomics 2009 Nov 24 (Epub ahead of print).
34. Rencurel F, Foretz M, Kaufmann MR, et al.: Stimulation of AMP-activated protein kinase is essential for the induction of drug metabolizing enzymes by phenobarbital in human and mouse liver. Mol Pharmacol 2006, 70: 1925-1934.
35. Maglich JM, Watson J, McMillen PJ, et al.: The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction. J Biol Chem 2004, 279: 19832-19838.
36. Ding X, Lichti K, Kim I, et al.: Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor alpha, and the coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha. J Biol Chem 2006, 281: 26540-26551.
37. Qatanani M, Zhang J, Moore DD: Role of the constitutive androstane receptor in xenobiotic-induced thyroid hormone metabolism. Endocrinology 2005, 146: 995-1002.
38. Kassam A, Winrow CJ, Fernandez-Rachubinski F, et al.: The peroxisome proliferator response element of the gene encoding the peroxisomal beta-oxidation enzyme enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase is a target for constitutive androstane receptor beta/9-cis-retinoic acid receptor-mediated transactivation. J Biol Chem 2000, 275: 4345-4350.
39. Ueda A, Hamadeh HK, Webb HK, et al.: Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. Mol Pharmacol 2002, 61: 1-6.
40. Bhalla S, Ozalp C, Fang S, et al.: Ligand-activated pregnane X receptor interferes with HNF-4 signaling by targeting a common coactivator PGC-1alpha. Functional implications in hepatic cholesterol and glucose metabolism. J Biol Chem 2004, 279: 45139-45147.
41. Miao J, Fang S, Bae Y, Kemper JK: Functional inhibitory cross-talk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1alpha. J Biol Chem 2006, 281: 14537-14546.
42. Masson D, Qatanani M, Sberna AL, et al.: Activation of the constitutive androstane receptor decreases HDL in wild-type and human apoA-I transgenic mice. J Lipid Res 2008, 49: 1682-1691.
43. • Maglich JM, Lobe DC, Moore JT: The nuclear receptor CAR (NR1I3) regulates serum triglyceride levels under conditions of metabolic stress. J Lipid Res 2009, 50: 439-445. The authors show that the altered serum profile of ob/ob mice is completely normalized when crossed with CAR-null mice. Conversely, ligand-induced activation of CAR results in increased serum triglycerides.
44. Wieneke N, Hirsch-Ernst KI, Kuna M, et al.: PPARalpha-dependent induction of the energy homeostasis-regulating nuclear receptor NR1i3 (CAR) in rat hepatocytes: potential role in starvation adaptation. FEBS Lett 2007, 581: 5617-5626.
45. • Gao J, He J, Zhai Y, et al.: The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity. J Biol Chem 2009, 284: 25984-25992. This article demonstrates that pharmacologic activation of CAR prevents obesity and ameliorates insulin sensitivity in mouse models.
46. Peet DJ, Turley SD, Ma W, et al.: Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998, 93: 693-704.
47. Goodwin B, Watson MA, Kim H, et al.: Differential regulation of rat and human CYP7A1 by the nuclear oxysterol receptor liver X receptor-alpha. Mol Endocrinol 2003, 17: 386-394.
48. Lu TT, Makishima M, Repa JJ, et al.: Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000, 6: 507-515.
49. Goodwin B, Jones SA, Price RR, et al.: A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000, 6: 517-526.
50. Hubbert ML, Zhang Y, Lee FY, Edwards PA: Regulation of hepatic Insig-2 by the farnesoid X receptor. Mol Endocrinol 2007, 21: 1359-1369.
51. Zhang Y, Edwards PA: FXR signaling in metabolic disease. FEBS Lett 2008, 582: 10-18.
52. Pineda Torra I, Claudel T, Duval C, et al.: Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 2003, 17: 259-272.
53. •• Action to Control Cardiovascular Disease Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358: 2545-2559. This large randomized clinical trial showed an increased risk of mortality from cardiovascular events with intensive glucose control in patients with type 2 diabetes and CVD or additional cardiovascular risk factors.
54. •• ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358: 2560-2572. This large randomized clinical trial showed that intensive glucose control is effective in reducing microvascular events but does not reduce major macrovascular events and mortality from cardiovascular causes in patients with type 2 diabetes.
55. • Henry RR, Lincoff AM, Mudaliar S, et al.: Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009, 374: 126-135. This phase 2 randomized clinical trial shows the favorable efficacy and safety profile of a new double PPARα/γ agonist in the treatment of type 2 diabetes.